	US 12,342,800 B2
	Immunodeficient non-human animal
Yuelei Shen, Beijing (CN); Yang Bai, Beijing (CN); Meiling Zhang, Beijing (CN); Jiawei Yao, Beijing (CN); Rui Huang, Beijing (CN); and Yanan Guo, Beijing (CN)
Assigned to Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Filed by Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing (CN)
Filed on Sep. 24, 2020, as Appl. No. 17/030,995.
Application 17/030,995 is a continuation of application No. 16/435,080, filed on Jun. 7, 2019, granted, now 10,820,580.
Application 16/435,080 is a continuation of application No. PCT/CN2018/079365, filed on Mar. 16, 2018.
Claims priority of application No. 201710160547.1 (CN), filed on Mar. 17, 2017; and application No. 201810215804.1 (CN), filed on Mar. 15, 2018.
Prior Publication US 2021/0105982 A1, Apr. 15, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A01K 67/0276 (2024.01); A01K 67/0271 (2024.01); A01K 67/0275 (2024.01); A61K 49/00 (2006.01); C07K 14/715 (2006.01)

CPC A01K 67/0276 (2013.01) [A01K 67/0275 (2013.01); C07K 14/7155 (2013.01); A01K 67/0271 (2013.01); A01K 2207/12 (2013.01); A01K 2217/075 (2013.01); A01K 2217/15 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0331 (2013.01); A61K 49/0008 (2013.01); C12N 2310/20 (2017.05)]

21 Claims

1. A genetically-modified non-human animal or a progeny thereof, whose genome comprises a disruption in the animal's endogenous CD132 gene, wherein the animal after being engrafted with human hematopoietic stem cells or peripheral blood cells is capable of developing a human immune system that has the following characteristics:

(a) the percentage of human CD45+ cells is greater than 70% of leukocytes of the animal;

(b) the percentage of human CD3+ cells is greater than 45% of leukocytes in the animal; and

(c) the percentage of human CD19+ cells is greater than 20% of leukocytes in the animal, wherein the disruption in the animal's endogenous CD132 gene comprises deletion of more than 150 nucleotides in exon 1, deletion of the entirety of intron 1, exon 2, intron 2, exon 3, intron 3, exon 4, intron 4, exon 5, intron 5, exon 6, intron 6, exon 7, intron 7, and deletion of more than 250 nucleotides in exon 8, wherein the animal is a NOD/scid mouse.